Oncogenic osteomalacia: The role of the phosphatonins. Diagnostic usefulness of the Fibroblast Growth Factor 23 measurement in one patient;L'ostéomalacie oncogène: Rôle des phosphatonines. Intérêt du dosage du fibroblast growth factor 23 démontré chez un malade

Revue de Medecine Interne

Volumn 26, Issue 3, 2005, Pages 238-241

  Dupond, J L ^a   Magy, N ^a   Mahammedi, M ^a   Prie, D ^b   Gil, H ^a   Meaux Ruault, N ^a   Kantelip, B ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

FGF 23; Hypophophatemia; Oncogenic osteomalacia; Paraneoplastic syndrome; Phosphatonins; Phosphaturic mesenchymal tumors

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; FLUORINE 18;

AGED; ANAMNESIS; ARTICLE; CALCIUM BLOOD LEVEL; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; FRACTURE; HUMAN; HYPOPHOSPHATEMIA; MALE; MANDIBLE; MEASUREMENT; OSTEOMALACIA; PHOSPHATE BLOOD LEVEL; PHOSPHATURIA; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; TUMOR LOCALIZATION;

EID: 17044428617     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.revmed.2004.11.013     Document Type: Article

References (22)

1. A.L. Folpe, J.C. Fanburg-Smith, S.D. Billings, M. Bisceglia, F. Bertoni, and J.Y. Cho Most osteomalacia-associated mesenchymal tumors are a single histopathology entity: an analysis of 32 cases and a comprehensive review of the literature Am. Surg. Pathol. 28 2004 1 30
2. S.C. SchiavI, and R. Kumar The phosphatonin pathway: new insights in phosphate homeostasis Kidney Int. 65 2004 1 14
3. T.O. Carpenter Oncogenic osteomalacia. A complex dance of factors New Engl. J. Med. 348 2003 1705 1708
4. K.B. Jonsson, R. Zahradnik, T. Larsson, K.E. White, T. Sugimoto, and Y. Imahishy Fibroblast Growth Factor in oncogenic osteomalacia and X-linked hypophosphatemia New Engl. J. Med. 348 2003 1655 1663
5. T. Shimada, S. Mizutani, T. Muto, T. Yoneya, R. Hino, and S. Takeda Cloning and characterisation of FGF-23 as a causative factor of tumor-induced osteomalacia Proc. Natl. Acad. Sci. USA 98 2001 6500 6505
6. T.J. Weber, S. Liu, O. Indridason, and L.D. Quarles Serum FGF-23 levels in normal and disordered phosphorus homeostasis J. Bone Miner. Res. 18 2003 1227 1234
7. 111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia Clin. Nucl. Med. 24 1999 130 131
8. J. Casari, V. Rossi, M. Varenna, M. Gasparini, A. Parafioriti, and A. Failoni A case of oncogenic osteomalacia detected by 111 IN-pentetreotide total body scan Clin. Exp. Rheumatol. 21 2003 493 496
9. T. Beyer, G. Antoch, S. Muller, T. Egelhof, L.S. Freudenberg, and J. Debatin Acquisition protocol considerations for combined PET/CT imaging J. Nucl. Med. 45 suppl 1 2004 25S 35S
10. A.C. Koeger, A. Prier, P.H. Vinceneux, and J.P. Camus Les ost́omalacies tumorales hypophosphoŕmiques Press Med. 14 1985 1747 1751
11. Y.K. Park, K.K. Unni, J.W. Beabout, and J.F. Hodgson Oncogenic osteomalacia. A clinicopathological study of 17 bone lesions J. Korean Med. Sci. 9 1994 289 298
12. D. Weiss, R.S. Bar, N. Weidner, M. Wener, and F. Lee Oncogenic osteomalacia: strange tumor in strange places Post-Graduate Med. J. 61 1985 349 355
13. M.K. Drezner Tumor-induced osteomalacia M.J. Favus Primer on the metabolic bone diseases and disorders of mineral metabolism. 4th ed 1999 Lippicott William and Wilkins Philadelphia 33 37
14. N. Weidner, and D. Santa Cruz Phosphaturic mesenchymal tumors:: a polymorphous group causing osteomalacia or rickets Cancer 59 1987 1442 1454
15. T. Berndt, T.A. Craig, A.E. Bowe, J. Vassiliadis, D. Reczek, and R. Finnegan Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent J. Clin. Invest. 112 2003 785 794
16. P.S.N. Rowe, Y. Kumagai, G. Gutierrez, I.R. Garret, R. Blacher, and D. Rosen MEPE has the properties of an osteoblastic phosphatonin and minhibin Bone 34 2004 303 319
17. K.E. White, K.B. Jonsson, G. Carn, G. Hampson, T.D. Spector, and M. Mannstadt The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting J. Clin. Endocrinol. Metab. 86 2001 497 500
18. L.M. Ward, F. Raunch, K.E. White, G. Filler, M.A. Matzinger, and M. Letts Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF-23 producing tumor of the distal ulna Bone 34 2004 905 911
19. Y. Yamazaki, R. Okazaki, M. Shibata, Y. Hasegawa, K. Satoh, and T. Tajima Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphoremic rickets-osteomalacia J. Clin. Endocrinol. Metab. 87 2002 4957 4960
20. Y. Takeuchy, H. Suzuki, S. Ogura, R. Imai, Y. Yamashita, and T. Yamashita Venous sampling for Fibroblast Growth Factor 23 confims preoperative diagnosis of tumor-induced osteomalacia J. Clin. Endocrinol. Metab. 89 2004 3979 3982
21. A.E. Bowe, R. Finnegan, S.M. Jan de beur, J. Cho, M.A. Levine, and R. Kumar FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate Biochem. Biophys. Res. Commun. 284 2001 977 981
22. T. Shimida, T. Muto, T. Urukawa, T. Yoneya, Y. Yamazaki, and K. Okawa Mutant FGF-23 responsible for autosomal dominant hypophosphatemia is resistant to proteolytic cleavage and causes hypophosphatemia in vivo Endocrinology 143 2002 3179 3182